Rare diseases
Investigational molecules
Locations
3013 Science Park Road, 92121-1101, United States
RayzeBio Inc. focuses its clinical research on gastroenteropancreatic neuroendocrine tumors, with attention to advanced, inoperable disease and tumors expressing somatostatin receptors. The company’s current trial activity centers on patients whose disease has progressed after prior 177Lu-labeled somatostatin analogue therapy.
The research program is directed toward treatment options for patients with limited local therapeutic choices in metastatic and unresectable neuroendocrine neoplasms.
Rayzebio Inc. runs clinical trials in conditions such as Gastroenteropancreatic neuroendocrine tumour disease, among others.
Clinical trials registered by this sponsor – none is enrolling right now.
BelgiumIncrease visibility for your trials and help patients find your site through our platform.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
